Search Results
Your search for ,Per matches 3772 pages
Showing 1151 - 1200Some Patients With Lung Cancer Report Feeling Uninformed About Their Disease, Uninvolved With Their Treatment
More than 1 in 10 patients with lung cancer do not know what type of tumor they have, according to data from a 17-country study carried out by the Global Lung Cancer Coalition (GLCC) presented by Beattie et al at the European Lung Cancer Virtual Congress 2021 (Abstract 209P_PR). Nearly one in five...
KEYNOTE-177: New Analysis Confirms Benefit of Pembrolizumab vs Chemotherapy in Microsatellite Instability–High Advanced Colorectal Cancer
In an updated analysis of the pivotal phase III KEYNOTE-177 trial of pembrolizu-mab for microsatellite instability–high (MSI-H) metastatic colorectal cancer, the benefit of first-line pembrolizumab continued beyond disease progression on the subsequent line of treatment, despite a high crossover to ...
Gastrointestinal Oncology Highlights 2020–2021 Almanac
Cancers of the digestive tract account for 338,090 new cases and 169,280 deaths annually in the United States. Although the overall mortality from these cancers is decreasing, this has been countered by an increase in the incidence of colorectal cancer in young adults. The rising incidence and poor ...
Inclusion of Surveillance Ejection Fraction in Predicting Risk of 10-Year Left-Ventricular Systolic Dysfunction in Survivors of Childhood Cancer
In a Dutch study reported in JACC: CardioOncology, Leerink et al found that the addition of ejection fraction measurement at the time of first surveillance echocardiogram improved prediction of 10-year risk of left-ventricular systolic dysfunction vs prediction based on cumulative anthracycline and ...
Female Breast Cancer Surpasses Lung Cancer as the Most Commonly Diagnosed Cancer Worldwide
Cancer ranks as a leading cause of death in every country in the world, and, for the first time, female breast cancer is the most commonly diagnosed cancer, overtaking lung cancer, according to a collaborative report from the American Cancer Society (ACS) and the International Agency for Research...
American Cancer Society Announces New Diversity in Cancer Research Program
The American Cancer Society recently launched the Diversity in Cancer Research program, a permanent umbrella that will support the American Cancer Society’s effort to foster a more diverse scientific workforce community. This has been made possible through an endowment contribution from Elizabeth...
Next Up in NSCLC: Antibody-Drug Conjugates
Antibody-drug conjugates directed against HER2, HER3, and trophoblast cell-surface antigen 2 (TROP2) are showing encouraging antitumor activity in advanced non–small cell lung cancer (NSCLC), according to research presented during the virtual edition of the International Association for the Study...
Nivolumab Plus Cabozantinib as First-Line Treatment of Advanced Renal Cell Carcinoma
On January 22, 2021, the U.S. Food and Drug Administration approved the combination of nivolumab and cabozantinib as first-line treatment for patients with advanced renal cell carcinoma.1-3 Supporting Efficacy Data Approval was based on the findings of the phase III, open-label CheckMate 9ER trial...
Adding Apalutamide to Abiraterone/Prednisone Extends Radiographic Progression-Free but Not Overall Survival
The phase III ACIS trial met its primary endpoint at 6 months showing that apalutamide plus abiraterone acetate/prednisone (AAP) extended radiographic progression-free survival vs abiraterone acetate/prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate...
SWOG 1500: Cabozantinib Extends Progression-Free Survival vs Sunitinib in Metastatic Papillary Renal Cell Carcinoma
Cabozantinib achieved a statistically significant and clinically meaningful extension in progression-free survival compared with sunitinib in patients with metastatic papillary renal cell carcinoma, a relatively uncommon type of renal cell carcinoma, according to the randomized phase II SWOG 1500...
Study Establishes Global Burden of Gallbladder and Biliary Tract Cancer
Although cancers of the gallbladder or bile ducts are rare, their rates of occurrence are increasing. A recent study published by Ouyang et al in the journal Cancer provided details on the burden of gallbladder and biliary tract cancer across 195 countries and territories from 1990 to 2017....
Identification of Genomic Subgroups of Patients With Myelodysplastic Syndromes: New Prognostic Modeling
In a study reported in the Journal of Clinical Oncology, Bersanelli et al reported that researchers in the EuroMDS Project found that patients with myelodysplastic syndromes (MDS) could be classified into eight distinct subtypes based on genomic characteristics. They also developed a new prognostic ...
FDA Approves Pembrolizumab Combination for Advanced Esophageal or Gastroesophageal Junction Carcinoma
On March 22, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal junction (tumors with epicenter 1–5 cm above the...
Association of Cardiovascular Risk Factors With Risk of Subsequent Cancer
In a study reported in JACC: CardioOncology, Emily S. Lau, MD, and colleagues found that the presence of cardiovascular disease risk factors was significantly associated with an increased risk of future cancer, although no increased risk was observed among individuals who had a history of...
Noncovalent BTK Inhibitor Pirtobrutinib in Relapsed or Refractory B-Cell Malignancies
In the phase I/II BRUIN trial reported in The Lancet, Anthony R. Mato, MD, and colleagues found that the noncovalent Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib produced durable responses in patients with relapsed or refractory B-cell malignancies, including those previously treated with ...
FDA Approves TheraSphere Y-90 Glass Microspheres for Unresectable Hepatocellular Carcinoma
Today, the U.S. Food and Drug Administration (FDA) approved TheraSphere Y-90 Glass Microspheres, developed for the treatment of patients with hepatocellular carcinoma. The approval expands access to this therapy, which, to date, has been utilized under a humanitarian device exemption—an FDA...
Circulating Hybrid Cells May Help to Monitor Treatment Response in Patients With Rectal and Esophageal Cancers
An analysis of 58 peripheral blood specimens from patients with rectal and esophageal cancers demonstrated that circulating hybrid cells may be a novel, noninvasive biomarker with potential for monitoring treatment response and disease progression to help guide decisions for further therapy,...
Is HPV Vaccination for Adults Aged 26 and Older Cost-Effective?
Vaccinating adults aged 26 and older against the human papillomavirus (HPV) may not be cost-effective, according to a new study published by Kim et al in PLOS Medicine. “Our study found that the added health benefit of increasing the vaccination age limit beyond 26 years is minimal, and that the...
Value of Global Scale-up of Cancer Care: Investment in Treatment, Imaging, and Quality of Care
In a simulation-based analysis reported in The Lancet Oncology, Ward et al found that the scaling up of cancer treatment packages, imaging modalities, and quality of care to the levels found in high-income countries would markedly reduce cancer mortality in low- to middle-income countries, as well...
High- vs Standard-Dose Thoracic Radiotherapy for Limited-Stage Small Cell Lung Cancer
In a phase II trial reported in The Lancet Oncology, Grønberg et al found that use of high-dose vs standard-dose twice daily thoracic radiotherapy as part of first-line chemoradiotherapy was associated with significantly improved overall survival and similar toxicity in patients with limited-stage...
Study Finds Regularly Drinking Sugar-Sweetened Soda May Increase Total and Breast Cancer Mortality
New research published by Koyratty et al in Cancer Epidemiology, Biomarkers & Prevention suggests that patients with breast cancer who drink sugar-sweetened beverages regularly are at increased risk for death from any cause, and from breast cancer in particular. Compared to women who never or...
Immunotherapy for Advanced Kidney Cancer: Effect of Body Mass Index
In a study reported in a research letter in JAMA Oncology, Lalani et al found that higher body mass index (BMI) was associated with better overall survival among patients with metastatic renal cell carcinoma receiving anti–PD-1/PD-L1–based immune checkpoint inhibitor treatment. No association of...
Belantamab Mafodotin-blmf Plus Pomalidomide and Dexamethasone Elicits Responses in Myeloma
Belantamab mafodotin-blmf combined with pomalidomide and dexamethasone led to a very good partial response or better in approximately three-quarters of patients with multiple myeloma that was double-class or triple-class refractory, according to Suzanne Trudel, MSc, MD, FRCPC, of Princess Margaret...
Oncologist Survey Identifies Knowledge Gaps in Cholangiocarcinoma Mutations
In the treatment of cholangiocarcinoma, many clinicians may be unaware of the importance of the major oncogenic mutations and other alterations that can be identified and targeted, according to a survey of oncologists presented at the 2021 Gastrointestinal Cancers Symposium.1 “Recent developments...
Fallout From COVID-19: Decline in Cancer Screening and Increase in Cancer-Related Deaths
Various studies at institutions in the United States and abroad have shown a substantial decline in cancer screening rates during the COVID-19 pandemic, suggesting that fewer cancers will be detected by screening and when they do manifest, they will be at more advanced stages. Indeed,...
Once-Weekly Selinexor Plus Bortezomib/Dexamethasone vs Twice-Weekly Bortezomib/Dexamethasone in Multiple Myeloma
As reported in The Lancet by Sebastian Grosicki, MD, of the Medical University of Silesia, Katowice, Poland, and colleagues, the phase III BOSTON trial has shown significantly prolonged progression-free survival with once-weekly selinexor plus bortezomib/dexamethasone vs twice-weekly...
Novel Therapies Under Study in Chronic Myeloid Leukemia
“There is progress whether ye are going forward or backward! The thing is to move.” —Edgar Cayce To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are a few abstracts selected from the meeting...
USPSTF Issues Final Recommendation Statement on Screening for Lung Cancer
Today, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for lung cancer in people who do not have signs or symptoms. Based on the evidence, the USPSTF recommends yearly screening using a low-dose computed tomography (CT) scan for people aged...
New Global Breast Cancer Initiative Highlights Renewed Commitment to Improve Survival
A major new collaborative effort, the Global Breast Cancer Initiative, was introduced by the World Health Organization (WHO), with the objective of reducing global breast cancer mortality by 2.5% per year until 2040, thereby averting an estimated 2.5 million deaths. In recognition of International ...
Cardiovascular Events With Transdermal Estradiol vs LHRH Agonists for Androgen Suppression in Advanced Prostate Cancer
In an analysis from the UK phase II/III PATCH trial reported in The Lancet, Langley et al found no differences in cardiovascular event rates over long-term follow-up with the use of a transdermal estradiol patch vs luteinizing hormone-releasing hormone agonists (LHRHa) for androgen suppression in...
FDA Pipeline: Designations in Ovarian, Head/Neck, and Thyroid Cancers
Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a novel immunotherapy for the treatment of ovarian cancer as well as Breakthrough Therapy designation to treatments for HRAS-mutant head and neck squamous cell carcinoma and previously treated thyroid cancer....
Study Identifies Mechanisms Tied to Immunotherapy Resistance Among Patients With Melanoma
Researchers have created a new technique that may help to uncover mechanisms cancer cells use to evade immunotherapies, which could lead to the development of more effective treatments. Investigators tested their new technique with cancer cells and matching immune cells from patients with melanoma...
Effect of Clinical Breast Examination Screening on Stage at Diagnosis and Breast Cancer Mortality
In an Indian study reported in the British Medical Journal, Mittra et al found that breast cancer screening with clinical breast examination vs active surveillance resulted in younger age and significant downstaging of disease at diagnosis of breast cancer, a significant reduction in breast cancer...
Mental Health Service Use Among Testicular Cancer Survivors
In a Canadian population-based cohort study reported in the Journal of Clinical Oncology, Raphael et al found that survivors of testicular cancer were more likely to use mental health services in both the short and long term following treatment compared with the general population. Study Details...
UN Human Rights Experts Comment on Environmental Racism in Louisiana’s ‘Cancer Alley’
“Cancer Alley,” located in Louisiana along the lower Mississippi River, serves as an industrial hub, with nearly 150 oil refineries, plastics plants, and chemical facilities. The ever-widening corridor of petrochemical plants has not only polluted the surrounding water and air, but also subjected...
EMPOWER-Lung 1: First-Line Cemiplimab-rwlc vs Platinum-Doublet Chemotherapy in Advanced NSCLC With PD-L1 Expression ≥ 50%
As reported in The Lancet by Sezer et al, the phase III EMPOWER-Lung 1 trial has shown improved overall and progression-free survival with cemiplimab-rwlc vs platinum doublet chemotherapy among patients with advanced non–small cell lung cancer (NSCLC) with PD-L1 expression on ≥ 50% of tumor cells...
KEYNOTE-177: New Analysis Confirms Benefit of Pembrolizumab vs Chemotherapy in Microsatellite Instability–High Advanced Colorectal Cancer
In an updated analysis of the pivotal phase III KEYNOTE-177 trial in microsatellite instability–high (MSI-H) metastatic colorectal cancer, the benefit of first-line pembrolizumab continued beyond disease progression on the subsequent line of treatment, despite a high crossover to immunotherapy for...
Endoscopic Nasopharyngectomy vs IMRT for Previously Treated, Resectable, Locally Recurrent Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The Lancet Oncology, Liu et al found that endoscopic nasopharyngectomy was associated with improved overall survival vs intensity-modulated radiotherapy (IMRT) in patients with resectable locally recurrent nasopharyngeal carcinoma who had received prior...
Biden Administration, New Congress Review Recent Rules Affecting Cancer Care Delivery
In the days and weeks leading up to President Biden’s inauguration, the Department of Health and Human Services (HHS)—under the prior administration—issued a number of rules and regulations that affect cancer care delivery. Many of those rules and regulations are now subject to review by the new...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Kenya
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Kenya. The aim of this special feature is to highlight the global cancer burden for various countries of the...
KEYNOTE-598: No Improvement With Addition of Ipilimumab to Pembrolizumab in NSCLC
In the phase III KEYNOTE-598 study, the addition of ipilimumab to pembrolizumab increased toxicity without boosting efficacy as first-line therapy for metastatic non–small cell lung cancer (NSCLC) in patients with high expression of PD-L1. The findings were presented at the International...
Responses to Anti–PD-1/PD-L1 Immunotherapy in Patients With MSS Solid Tumors and High Tumor Mutational Burden
In a single-institution study reported in JAMA Oncology, Valero et al found that response rates to anti–PD-1 or anti–PD-L1 treatments in patients with microsatellite-stable (MSS) solid tumors were generally higher among those with high tumor mutational burden (TMB) defined as ≥ 10...
Bevacizumab Beyond Disease Progression Plus Carboplatin-Based Doublet in Platinum-Sensitive Ovarian Cancer
In the phase III MITO16b/MANGO–OV2/ENGOT–ov17 trial, investigators found that treatment with a carboplatin-based doublet plus bevacizumab beyond disease progression significantly improved progression-free survival vs a carboplatin-based doublet alone in women with platinum-sensitive ovarian cancer...
MRI-Targeted Biopsy vs Systematic Transrectal Ultrasonography Biopsy for Detection of Disease in Men at Risk for Prostate Cancer
In a Canadian phase III trial reported in JAMA Oncology, Klotz et al found that multiparametric magnetic resonance imaging (MRI) with targeted biopsy was noninferior to systematic 12-core transrectal ultrasonography biopsy in detecting International Society of Urological Pathology grade group 2...
FDA Approves Cemiplimab-rwlc for Patients With NSCLC and High PD-L1 Expression
On February 22, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for the first-line treatment of patients with advanced non–small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score [TPS] > 50%) as determined by an FDA-approved...
New Recommendations Aim to Eliminate Racial Disparities in Multiple Myeloma Therapies and Trials
Recommendations designed to address the underrepresentation of Black patients in clinical trials for multiple myeloma were recently released. Details about the initiative, published by Gormley et al in Blood Cancer Discovery, form a road map for designing multiple myeloma clinical trials to...
PET-Guided Omission of Consolidation Radiotherapy in Early-Stage Unfavorable Hodgkin Lymphoma
In a phase III German Hodgkin Study Group trial (GHSG HD17) reported in The Lancet Oncology, Peter Borchmann, MD, and colleagues found that positron-emission tomography (PET)-guided omission of consolidation radiotherapy was associated with noninferior progression-free survival among patients with...
Belantamab Mafodotin-blmf Plus Pomalidomide and Dexamethasone Elicits Responses in Myeloma
Belantamab mafodotin-blmf combined with pomalidomide and dexamethasone led to a very good partial response (VGPR) or better in approximately three-quarters of patients with multiple myeloma that was double-class or triple-class refractory, according to Suzanne Trudel, MSc, MD, FRCPC, of Princess...
Expert Point of View: David Snyder, MD
David Snyder, MD, Acting Chair, City of Hope Department of Hematology & Hematopoietic Cell Transplantation, Duarte, California, who was not involved in the ASCEMBL study, commented on the promise of asciminib: “The hope is this drug would be able to overcome resistance to other tyrosine kinase...
Study Finds Asciminib Safer, More Effective Than Bosutinib in Chronic-Phase CML
Since the introduction of imatinib almost 18 years ago, similar next-generation tyrosine kinase inhibitors have been approved for chronic myeloid leukemia (CML), including dasatinib, nilotinib, bosutinib, and ponatinib. These drugs attack a similar target, making it more likely that resistance to...
